BioNTech SE (ETR:22UA)
Germany · Delayed Price · Currency is EUR 76.75
+0.60 (0.79%)
Last updated: Jun 3, 2026, 12:58 PM CET
BioNTech SE Revenue
BioNTech SE had revenue of 148.50M EUR in the quarter ending March 31, 2026, a decrease of -39.24%. This brings the company's revenue in the last twelve months to 2.69B, up 4.82% year-over-year. In the year 2025, BioNTech SE had annual revenue of 3.05B with 5.63% growth.
Revenue (ttm)
2.69B
Revenue Growth
+4.82%
P/S Ratio
6.90
Revenue / Employee
359.32K
Employees
7,807
Market Cap
19.36B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.05B | 162.80M | 5.63% |
| Dec 31, 2024 | 2.89B | -1.03B | -26.31% |
| Dec 31, 2023 | 3.92B | -13.39B | -77.33% |
| Dec 31, 2022 | 17.31B | -1.67B | -8.78% |
| Dec 31, 2021 | 18.98B | 18.49B | 3,834.63% |
| Dec 31, 2020 | 482.30M | 373.70M | 344.11% |
| Dec 31, 2019 | 108.60M | -18.98M | -14.87% |
| Dec 31, 2018 | 127.58M | 65.98M | 107.11% |
| Dec 31, 2017 | 61.60M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bayer Aktiengesellschaft | 45.24B |
| Siemens Healthineers AG | 23.07B |
| Fresenius SE & Co. KGaA | 22.99B |
| Merck KGaA | 20.96B |
| Fresenius Medical Care AG | 19.36B |
| Sartorius Aktiengesellschaft | 3.55B |
| Fielmann Group AG | 2.44B |
| Carl Zeiss Meditec AG | 2.17B |
BioNTech SE News
- 2 days ago - BioNTech, Bristol announce interim Phase 2 data from Rosetta Lung-02 trial - TheFly
- 3 days ago - Global Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial - GlobeNewsWire
- 6 days ago - This Biotech's Cancer Portfolio Could End Its Rough Patch - Barrons
- 7 days ago - BioNTech upgraded to Buy from Neutral at UBS - TheFly
- 12 days ago - BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 12 days ago - Bernstein starts BioNTech at Market Perform, sees high registration risk - TheFly
- 12 days ago - BioNTech initiated with a Market Perform at Bernstein - TheFly
- 18 days ago - BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2026 - GlobeNewsWire